Compare Archer-Daniels-Midland Co (ADM) vs Pfizer Inc (PFE) Price & Performance

ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.

Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.

Pfizer (PFE) trades at $23.72, down 2.47% on the day, with a bearish technical signal from moving averages but recent earnings beats. The stock has a P/E of 18.11 and net income margin of 11.83%, supported by strong cash flow from operations of $11.70B in 2025. Recent news highlights pipeline progress in obesity and oncology, with dividends of $0.43 paid semi-annually.

The outlook is mixed: analyst consensus is a 'Hold' with a $27.63 price target, implying potential upside, but risks include patent cliffs and competitive pressures. Revenue has declined from pandemic peaks, yet cost controls sustain profitability. Investors may find value if pipeline catalysts materialize, though near-term volatility persists.